Establishes State-of-the-Art Cell Processing Facility at New Headquarters, Aiming to Expand Domestic Market Share
[Medical Newspaper & Daily Bosa Reporter Hyun-Ki Kim] Following the implementation of the revised “Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety Act” (commonly referred to as the “Advanced Regenerative Medicine Act” or “첨생법”), Korean regenerative medicine companies are securing new growth opportunities. Among them, REV-MED is further strengthening its position in the global biological products market as a leading regenerative medicine company.
REV-MED (CEO Edward BG Shin) announced that it is actively expanding its business scope by leveraging the broadened clinical research targets and simplified approval procedures introduced through the revised legislation.
In particular, as the scope of advanced regenerative medicine applications expands beyond severe, rare, and intractable diseases to include general medical conditions, REV-MED’s proprietary autologous biological extraction technologies are expected to see broader utilization.
As part of this vision, REV-MED has established a state-of-the-art cell processing facility at its new headquarters, reinforcing its commitment to leading the regenerative medicine industry.
The company has also obtained certifications in Japan and China based on its independently developed triple-chamber technology — a rare achievement among Korean biotechnology companies.
In addition, REV-MED has developed bio-kits capable of extracting cells from various tissues including blood, bone marrow, and adipose tissue. Its contamination-prevention design has earned recognition in the global market for its technological excellence.
These technological capabilities are expected to drive rapid revenue growth in conjunction with the expanded approval procedures for clinical and therapeutic use enabled by the revised Advanced Regenerative Medicine Act.
As a result of the regulatory changes, REV-MED’s autologous biological extraction technologies and bio-kit product portfolio are now positioned to be utilized across broader markets.
Furthermore, the revised law has opened pathways for limited patient administration during clinical stages through treatment-purpose approval procedures, enabling revenue generation even in the early stages of research.
To enhance credibility, REV-MED has published approximately 20 SCI(E)-level academic papers. These academic achievements are regarded as supporting the company’s technological expertise while helping build trust in the global market.
The global biological products market is projected to grow at an annual rate exceeding 10%, reaching approximately USD 615 billion by 2029.
In response to this trend, REV-MED has designated 2025 as the “first year of global expansion” and is focusing on expanding into European and Asian markets.
In particular, as the domestic regenerative medicine market becomes increasingly active following the amendment to the Advanced Regenerative Medicine Act, the company plans to simultaneously expand its market share in both domestic and international markets.
A company representative stated, “This amendment to the Advanced Regenerative Medicine Act represents an important turning point that creates new growth opportunities for Korea’s regenerative medicine market. We are fully prepared to lead this transformation.”
The representative added, “Based on our proprietary technologies and infrastructure, we will continue strengthening our competitiveness in the global biological products market while striving to provide innovative therapeutic solutions.”
Source: Medical Newspaper (Bosa)
Establishes State-of-the-Art Cell Processing Facility at New Headquarters, Aiming to Expand Domestic Market Share
[Medical Newspaper & Daily Bosa Reporter Hyun-Ki Kim] Following the implementation of the revised “Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety Act” (commonly referred to as the “Advanced Regenerative Medicine Act” or “첨생법”), Korean regenerative medicine companies are securing new growth opportunities. Among them, REV-MED is further strengthening its position in the global biological products market as a leading regenerative medicine company.
REV-MED (CEO Edward BG Shin) announced that it is actively expanding its business scope by leveraging the broadened clinical research targets and simplified approval procedures introduced through the revised legislation.
In particular, as the scope of advanced regenerative medicine applications expands beyond severe, rare, and intractable diseases to include general medical conditions, REV-MED’s proprietary autologous biological extraction technologies are expected to see broader utilization.
As part of this vision, REV-MED has established a state-of-the-art cell processing facility at its new headquarters, reinforcing its commitment to leading the regenerative medicine industry.
The company has also obtained certifications in Japan and China based on its independently developed triple-chamber technology — a rare achievement among Korean biotechnology companies.
In addition, REV-MED has developed bio-kits capable of extracting cells from various tissues including blood, bone marrow, and adipose tissue. Its contamination-prevention design has earned recognition in the global market for its technological excellence.
These technological capabilities are expected to drive rapid revenue growth in conjunction with the expanded approval procedures for clinical and therapeutic use enabled by the revised Advanced Regenerative Medicine Act.
As a result of the regulatory changes, REV-MED’s autologous biological extraction technologies and bio-kit product portfolio are now positioned to be utilized across broader markets.
Furthermore, the revised law has opened pathways for limited patient administration during clinical stages through treatment-purpose approval procedures, enabling revenue generation even in the early stages of research.
To enhance credibility, REV-MED has published approximately 20 SCI(E)-level academic papers. These academic achievements are regarded as supporting the company’s technological expertise while helping build trust in the global market.
The global biological products market is projected to grow at an annual rate exceeding 10%, reaching approximately USD 615 billion by 2029.
In response to this trend, REV-MED has designated 2025 as the “first year of global expansion” and is focusing on expanding into European and Asian markets.
In particular, as the domestic regenerative medicine market becomes increasingly active following the amendment to the Advanced Regenerative Medicine Act, the company plans to simultaneously expand its market share in both domestic and international markets.
A company representative stated, “This amendment to the Advanced Regenerative Medicine Act represents an important turning point that creates new growth opportunities for Korea’s regenerative medicine market. We are fully prepared to lead this transformation.”
The representative added, “Based on our proprietary technologies and infrastructure, we will continue strengthening our competitiveness in the global biological products market while striving to provide innovative therapeutic solutions.”
Source: Medical Newspaper (Bosa)